key: cord-0865574-w10o63og authors: Kim, Paul S.; Schildhouse, Richard J.; Saint, Sanjay; Bradley, Suzanne F.; Chensue, Stephen; Houchens, Nathan; Gupta, Ashwin title: Vaccine Breakthrough Infections in Veterans Hospitalized with Coronavirus Infectious Disease-2019: A Case Series date: 2021-10-13 journal: Am J Infect Control DOI: 10.1016/j.ajic.2021.10.003 sha: 72a6f630e5b2a69e664605d9c2ecc67942f5b874 doc_id: 865574 cord_uid: w10o63og BACKGROUND: While SARS-CoV-2 vaccine breakthrough infections are expected, reporting on breakthrough infections requiring hospitalization remains limited. This observational case series report reviewed ten individuals hospitalized with vaccine breakthrough infections to identify patient risk factors and serologic responses upon admission. METHODS: Electronic medical records of BNT162b2 (Pfizer-BioNTech) or mRNA-1732 (Moderna) vaccinated patients admitted to VAAAHS with newly diagnosed COVID-19 between 15 March 2021 and 15 April 2021 were reviewed. Patient variables, COVID-19 lab testing including anti-S IgM, anti-N IgG antibodies, and hospital course were recorded. Based on lab testing, infections were defined as acute infection or resolving/resolved infection. RESULTS: Of the ten patients admitted with breakthrough infections, all were > 70 years of age with multiple comorbidities. Mean time between second vaccine dose and COVID-19 diagnosis was 49 days. In the seven individuals with acute infection, none had observed serologic response to mRNA vaccination, five developed severe disease, and one died. Three individuals had anti-N IgG antibodies and a high polymerase chain reaction cycle threshold (C(t)) value, suggesting resolving/resolved infection. CONCLUSIONS: Given the variability of vaccine breakthrough infections requiring hospitalization, serologic testing may impart clarity on timing of infection and disease prognosis. Individuals at risk of diminished response to vaccines and severe COVID-19 may also benefit from selective serologic testing after vaccination to guide risk mitigation strategies in a post-pandemic environment. and appear approximately 10 to 14 days after initial infection (6) , and C t values inversely correlate with viral density (7) . Presence of anti-N IgG antibodies with high C t values suggests an expected further decrease in viral load and improvement in symptoms (8) . Resolving/resolved infections could include COVID-19 infections greater than 10 days from initial infection, but they could also include remote COVID-19 infections with persistently positive PCR tests. In cases with indeterminate results (e.g., negative anti-N IgG antibodies and a high C t value), clinical correlation was used to define whether the case was representative of an acute or resolving/resolved infection. The administering clinic of record and staff were also noted. During the study period, twenty patients were hospitalized with COVID-19, of which ten were fully vaccinated (7 BNT162b2 and 3 mRNA-1273) (Table) . The mean time between second vaccination dose and diagnosis of COVID-19 was 49 days. All patients with vaccine breakthrough infections were older than 70 years of age; nine were Caucasian and one African American. Six had a BMI greater than 30 kg/m 2 , all had multiple medical comorbidities, and one was immunosuppressed on nintedanib. Six individuals (patients 1, 2, 3, 5, 9, 10) had acute infections, of which five developed severe COVID-19 necessitating supplemental oxygen. Three individuals (patients 6, 7, 8) had resolving/resolved infections, of which two were admitted for conditions unrelated to their newly diagnosed COVID-19 infection (bacterial endocarditis, axillary abscess). The third individual (patient 6) was admitted for a concern of weakness, but never required oxygen supplementation to suggest a moderate to severe COVID-19 infection. One individual (patient 4) was indeterminate, with a positive PCR, high C t value, negative antigen, and absent IgM and IgG antibodies. Based on clinical presentation, this was favored to represent early acute infection rather than resolving/resolved infection without serologic response. All individuals were vaccinated through the VAAAHS, and there was no obvious relationship among vaccine breakthrough infection, vaccination location, administration date, and vaccinating personnel. Our case series examines patients hospitalized with SARS-CoV-2 vaccine breakthrough infections, in the context of a highly vaccinated population during a COVID-19 surge in Michigan. The ten Veterans hospitalized with vaccine breakthrough infections were elderly, had substantial comorbid conditions, and were often obese. One patient was on immunosuppressive therapy. It is notable that, of the patients with acute infection, none had an IgM response to the spike protein. Because high levels of anti-S IgM have been found for at least eight weeks after a second mRNA vaccine dose (9), there is a possibility of limited vaccine response in the individuals in this observational case series report. Genomic sequencing of these patients was not obtained; however, as the majority of infections during the surge were due to the variant Alpha strain, concern is raised for variant escape since mRNA vaccines are typically associated with high titers of neutralizing antibodies (10) . Alternatively, breakthrough infection may be the result of diminished immune response due to patient specific factors. All ten cases of vaccine breakthrough infection were in older adults, despite evidence that adults older than 65 years have similar immunogenicity to younger adults (11) . Emerging studies show association between risk factors such as immunosuppression (12) and hemodialysis (13) and diminished humoral response to the SARS-CoV-2 vaccine. In addition, in de-novo COVID-19 infections, antibody responses are similarly decreased in individuals who are obese (14) or diabetic (15) . As these risk factors are also related to more severe COVID-19, it is important to better understand which factors lead to diminished protection following SARS-CoV-2 vaccination, and whether these patients may benefit from additional vaccine doses or preventative measures. Given that high risk individuals are more likely to have a diminished humoral response to the SARS-CoV-2 vaccine and subsequently an elevated risk of severe COVID-19 infection, might postvaccination antibody testing be used in this population to determine those with diminished vaccination response so that they could be encouraged to continue precautions? Currently the Food and Drug Administration (FDA) recommends against routine antibody testing to assess immunity after SARS-CoV-2 vaccination (16) . However, without a better understanding of vaccine response, many high risk individuals could be at even greater risk as mitigation measures are relaxed (e.g., mandatory masking) for the fully vaccinated. For high risk individuals, the selective use of antibody testing for anti-S IgM and IgG may be useful to identify those that would benefit from enhanced precautions to SARS-CoV-2 exposure. Five of the seven patients with acute breakthrough infection in this case series had severe COVID-19 symptoms necessitating supplemental oxygen or ventilatory support. While the CDC reported that fully vaccinated adults 65 years and older are 94% less likely to be hospitalized with COVID-19 (17), it is noteworthy that only one individual was hospitalized in their study. While patients with breakthrough infections may tend to have milder symptoms, some will still develop severe symptoms that necessitate hospitalization. Our experience with Michigan Veteran patients demonstrates that despite higher than average vaccination rates within this population, surging case counts within the community will lead to an increase in breakthrough infections and hospitalizations. As the Delta strain and other highly virulent strains become more prevalent, this report reinforces the need to not only rapidly vaccinate entire communities, but also practice other risk mitigation strategies if local COVID-19 case volumes are high. In our observational case series report, three individuals (30%) had resolving/resolved infections and were admitted for reasons other than moderate to severe COVID-19. These data are consistent with CDC studies demonstrating that 29% of patients hospitalized with a diagnosis of post-vaccination breakthrough infections were asymptomatic or primarily hospitalized for reasons other than COVID-19 (3) . Given that SARS-CoV-2 PCR can remain positive in asymptomatic individuals for extended periods (18) , our report suggests that a subset of hospitalizations with COVID-19 breakthrough infections likely represent new diagnoses of resolving/resolved infections. For newly diagnosed COVID-19 infections, CDC recommends isolation precautions for 10 days after first positive viral test (19) . However, for these asymptomatic SARS-CoV-2 breakthrough infections in the hospital, serologic testing may impart clarity on the timing of infection and could aid infectious disease consultants in designing patient-specific infection control processes. This report has several strengths. Staff administering vaccines underwent the same training, vaccines were stored and handled meticulously, and needle length was adjusted to patient BMI. The lack of relationship between vaccine breakthrough infection and vaccination clinic, date, or vaccination personnel suggests associations observed were more likely related to the vaccine or the recipient rather than the vaccination process. There are also limitations to this case series, such as the lack of genomic sequencing to detect variants. Laboratory testing included anti-S IgM and anti-N IgG antibodies, but not anti-S IgG antibodies, which would have helped better define humoral response to the vaccine, given limited knowledge of IgM antibody persistence beyond eight weeks. Serial serologic testing was not done to determine the trajectory of an individual's antibody response. This may have helped to further characterize certain cases such as patient 7 who had a resolving/resolved infection but a negative anti-S IgM antibody. Immune protection also involves both serologic and cellular mechanisms, and further research is required to better understand the importance of either. In summary, we report ten patients with SARS-CoV-2 vaccine breakthrough infections requiring hospitalization, including those with acute infection but without observed serologic response, a majority of whom developed severe disease. Our experience suggests that even as vaccination rates climb nationwide, breakthrough infections may continue to occur, especially amidst variant strains and new COVID-19 surges. Additional understanding of factors leading to vaccine breakthrough infection is critical to guide risk mitigation strategies and to help care for those who require acute care hospitalization. Finally, the potential role of serologic antibody testing to identify high risk individuals or to tailor hospital infection control policies should be explored. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine COVID-19 Vaccine Breakthrough Case Investigation and Reporting Centers for Disease Control and Prevention. (n.d.). CDC COVID Data Tracker Antibody Response After SARS-CoV-2 Infection and Implications for Immunity : A Rapid Living Review Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs Cycle threshold values in RT-PCR to determine dynamics of SARS-CoV-2 viral load: An approach to reduce the isolation period for COVID-19 patients SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech). Viruses Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients Impaired anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with diabetes mellitus: A preliminary report Antibody Testing Not Recommended to Assess Immunity After Vaccination: FDA Safety Communication Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years -United States Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2 2021 Sept 14. Ending Isolation and Precautions for People with COVID-19: Interim Guidance